Clinical trials: Age ≥45
Solid Tumours
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Rifampicin on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02046850
- Testing
- selumetinib, rifampicin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cicatrix, Wound Healing
Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects
To assess safety and toleration, systemic exposure and anti-scarring potential of intradermal avotermin (Juvista) in young females.
- Trial name
- NCT00984581
- Testing
- Avotermin
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Renovo
Condylomata Acuminata, Cervical Cancer
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase I clinical study was designed to evaluate the safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD.…
- Trial name
- NCT03813940
- Testing
- HPV Vaccine,135μg/0.5ml, HPV Vaccine,270μg/1.0ml
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Xiamen University
HPV InfectioN, HPV-Related Carcinoma
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT05262010
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- 8 sites in China
- Volunteers
- 13,500 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Clostridium Infections
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a…
- Trial name
- NCT04026009
- Testing
- C. difficile investigational vaccine based on the F2 antigen (GSK2904545A), C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B
- Where
- Belgium
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumours
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Study to assess the effect of food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT01974349
- Testing
- selumetinib (oral)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Malaria
Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men
Animal and human studies have shown that the prime-boost immunization strategy using malaria antigens expressed in plasmid or viral vectors induces strong cellular immune responses.
- Trial name
- NCT00121771
- Testing
- FP9 CS, MVA CS
- Where
- The Gambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Papillomavirus Infections
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age.
- Trial name
- NCT03998254
- Testing
- V503, Gardasil
- Where
- 6 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prevention of COVID19
Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)
This study aims to evaluate the immunogenicity of Moderna mRNA-1273 vaccine in volunteers aged 65 years or more compared to volunteers aged 18-45 years, over 24 months duration.
- Trial name
- CoviCompareM (NCT04748471)
- Testing
- mRNA-1273
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infections, Meningococcal
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).
- Trial name
- NCT02639351
- Testing
- Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R, Investigational MenC-CRM adjuavnted with 25 ug of LHD153R, Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adults Aged 18-45 Years
The Safety and Efficacy of Probiotic for Improving Intestinal and Immune Function
To evaluate the safety and efficacy of Streptococcus salivarius subsp. thermophilus ST36 in healthy adults on immune function and intestinal health.
- Trial name
- NCT06779994
- Testing
- Probiotic
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Lower Urinary Tract Symptoms
Study to Evaluate Efficacy and Safety of NDS-446 in Men With Lower Urinary Tract Symptoms (LUTS)
Prospective, Randomized, Double-Blind, Placebo Controlled clinical trial to study the efficacy and the safety of NDS-446 (500 mg/cap) in Men 45 years of age or older with moderate to severe lower urinary tract symptoms (LUTS)
- Trial name
- NCT02808013
- Testing
- NDS-446
- Volunteers
- 116 people
- Sponsor
- Naturex-Dbs
Fragile X Syndrome
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome
- Trial name
- NCT05358886
- Testing
- BPN14770/ zatolmilast
- Where
- 17 sites in United States
- Volunteers
- 171 people
- Sponsor
- Tetra Discovery Partners
Human Papillomavirus Infection
APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results
In both the ASC-US Study and Adjunct Study populations, the objectives are to: evaluate the performance characteristics of the AHPV-GT Assay for detecting cervical disease in women with APTIMA HPV Assay positive results and…
- Trial name
- AHPV-GT (NCT01384370)
- Where
- 3 sites in United States
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Stress Urinary Incontinence
Pilates Pelvic Floor Strengthening Program to Improve Urinary Incontinence
Does a twice weekly, 12-week Pilates pelvic floor strengthening program improve short- and long-term measures of stress urinary incontinence symptoms in women ages 45-70 years of age?
- Trial name
- NCT03118557
- Testing
- Pilates pelvic floor strengthening
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Tuberculosis
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
This is a Phase I, single-center, double-blinded, randomized, placebo-controlled, five-period cross-over clinical study of PA-824 to evaluate the effect of PA-824 and of PA-824 plus moxifloxacin on cardiac repolarization (QT/QTc…
- Trial name
- NCT01674218
- Testing
- Moxifloxacin, PA-824
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Colorectal Adenoma, Colorectal Polyp
To Compare Artificial Intelligence Software Aided Adenoma Detection in Screening Colonoscopies Versus Standard Colonoscopy Without Artificial Intelligence Software Assistance in Participants Between 45 and 75 Years of Age
The aim of this study is to assess the efficacy of Ultivision Artificial Intelligence (AI) Software in detecting adenomas in screening colonoscopy procedures. The safety of Ultivision AI Software will also be assessed.
- Conditions
- Colorectal Adenoma, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal SSA
- Trial name
- AIDA (NCT04196088)
- Testing
- Ultivision Artificial Intelligence Software, No Artificial Intelligence Software enhancement
- Where
- 9 sites in United States
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Docbot, Inc.
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.